ABSTRACT
AIM: Over the past 2 decades, transcatheter occlusion of patent ductus arteriosus (PDA) with coils and the duct occluders evolved to be the procedure of choice. A new device, the Occlutech PDA® occluder (ODO) device has been designed. Herein, we aimed to evaluate the characteristics and short-term results of patients who underwent transcatheter closure of PDA using the ODO. METHODS: We reviewed the clinical records of 60 patients from different centers in Turkey between December 2013 and January 2016. The medical records were reviewed for demographic characteristics and echocardiographic findings. Device size was selected on the narrowest diameter of PDA. RESULTS: The median patient age was 2.5 years (6 months-35 years), and median PDA diameter was 2.5 mm (1.2-11 mm). Fifty-eight of 60 patients (96.6%) had successful ODO implantation. The occlusion rates were 37/58 (63.7%) at the end of the procedure, 51/58 (87.9%) at 24-48 hours post-procedure, and 57/58 (98.2%) on echocardiography at a median follow-up of 7.6 months. CONCLUSION: Our results indicate that transcatheter closure of PDA using the ODO is effective. Larger studies and longer follow-up are required to assess whether its shape and longer length make it superior to other duct occluders in large, tubular, or window-type ducts. (J Interven Cardiol 2016;29:325-331).
Subject(s)
Cardiac Catheterization/instrumentation , Ductus Arteriosus, Patent/surgery , Septal Occluder Device , Adolescent , Adult , Child , Child, Preschool , Echocardiography , Female , Follow-Up Studies , Humans , Infant , Male , Prosthesis Design , Treatment Outcome , Turkey , Young AdultSubject(s)
Arrhythmias, Cardiac/epidemiology , Heart Septal Defects, Ventricular/surgery , Postoperative Complications/epidemiology , Prosthesis Implantation/adverse effects , Arrhythmias, Cardiac/etiology , Cardiac Catheterization , Heart Conduction System , Humans , Postoperative Complications/etiology , Turkey/epidemiologyABSTRACT
In heterotaxia syndrome with left atrial isomerism, the distinguishing feature is interrupted inferior vena cava with azygos continuation. We report using a transjugular approach to device closure of an atrial septal defect in an 8-year-old boy with heterotaxia syndrome. We found that device closure of the child's atrial septal defect through a jugular venous approach was safe when an inferior vena cava approach was not possible. To our knowledge, ours is the first report of the use of internal jugular vein access to close an atrial septal defect in a child.
